| CAS NO: | 834903-43-4 |
| 包装 | 价格(元) |
| Free Sample (0.1-0.5mg) | 电议 |
| 10mM (in 1mL DMSO) | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 200mg | 电议 |
| Cas No. | 834903-43-4 |
| 别名 | 4-[4,6-二氢-4-(3-羟基苯基)-3-(4-甲基苯基)-6-氧代吡咯并[3,4-C]吡唑-5(1H)-基]苯甲酸 |
| Canonical SMILES | O=C(N1C(C=C2)=CC=C2C(O)=O)C(NN=C3C4=CC=C(C)C=C4)=C3C1C5=CC(O)=CC=C5 |
| 分子式 | C25H19N3O4 |
| 分子量 | 425.44 |
| 溶解度 | DMSO: 100 mg/mL (235.05 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | CID 16020046 is a potent and selective GPR55(LPI receptor) antagonist; inhibitsGPR55 constitutive activity with IC50 of 0.15 uM.IC50 value: 0.15 uM [1]Target: GPR55 antagonistIn yeast cells expressing human GPR55, CID16020046 antagonized agonist-induced receptor activation. In human embryonic kidney(HEK293) cells stably expressing human GPR55, the compound behaved as an antagonist on LPI-mediated Ca2+ release and extracellular signal-regulated kinases activation, but not in HEK293 cells expressing cannabinoid receptor 1 or 2.CID16020046 concentration dependently inhibited LPI-induced activation of nuclear factor of activated T-cells (NFAT), nuclear factor k of activated B cells (NF-kB) and serum response element, translocation of NFAT and NF-kB, and GPR55 internalization. It reduced LPI-induced wound healing in primary human lung microvascular endothelial cells and reversed LPI-inhibited platelet aggregation. [1]. Kargl J, et al. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J Pharmacol Exp Ther. 2013 Jul;346(1):54-66. |
m.cnreagent.com